GlassScriptPhysician profile
Jolly Varki
NPI 1912995101
$31,342.41
in general payments reported to CMS, 2019-2025
74 companies · $4,925 in 2025
The $4,925 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,249 · 2020: $2,832 · 2021: $3,647 · 2022: $4,666 · 2023: $5,468 · 2024: $5,556 · 2025: $4,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $1,277 · Long Term Medical Supply Or Device Loan: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,822.84 |
| Education | $1,276.53 |
| Long Term Medical Supply Or Device Loan | $849.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,722.49 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $3,022.85 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Novartis Pharmaceuticals Corporation | $2,977.37 | 2019-2025 | Kisqali, Piqray |
| Pfizer INC. | $2,576.08 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,872.76 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $1,728.89 | 2019-2025 | Xtandi, Xospata, Vyloy |
| Celgene Corporation | $1,686.47 | 2019-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $1,298.36 | 2019-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $783.28 | 2019-2025 | Enhertu, Datroway |
| Amgen INC. | $771.81 | 2019-2023 | Kyprolis, Vectibix, Xgeva |
| Seagen INC. | $621.65 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $539.25 | 2019-2025 | |
| Beigene USA, INC. | $523.35 | 2021-2024 | Brukinsa, Tevimbra |
| Incyte Corporation | $507.19 | 2019-2023 | Jakafi |
| Lilly USA, LLC | $491.10 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $464.78 | 2019-2023 | Rezlidhia, Tavalisse |
| Eisai INC. | $445.66 | 2019-2025 | |
| Genzyme Corporation | $405.14 | 2019-2025 | |
| Array Biopharma INC | $363.30 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Gilead Sciences, INC. | $355.32 | 2019-2025 | Trodelvy |
| Emd Serono, INC. | $349.80 | 2019-2025 | Bavencio |
| Abbvie INC. | $342.73 | 2019-2025 | |
| Myovant Sciences INC. | $313.69 | 2021-2022 | |
| Exelixis INC. | $305.04 | 2019-2023 | Cabometyx |
| Sumitomo Pharma America, INC. | $285.34 | 2023-2025 | Orgovyx |
| Genentech USA, INC. | $285.12 | 2019-2023 | Tecentriq, Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $280.72 | 2023-2025 | Ninlaro, Iclusig, Alunbrig |
| Glaxosmithkline, LLC. | $209.17 | 2020-2025 | Zejula, Ojjaara, Jemperli |
| Tolmar, INC. | $207.88 | 2023-2025 | Eligard, Rubraca |
| Coherus Oncology, INC. | $206.91 | 2020-2022 | |
| Kite Pharma, INC. | $204.66 | 2020-2025 | Yescarta |
| Karyopharm Therapeutics INC. | $201.39 | 2021-2024 | Xpovio |
| Boston Scientific Corporation | $185.15 | 2023-2025 | General - Interventional Oncology, Therasphere Y90 Glass Microspheres 10 Gbq |
| Tolmar Pharmaceuticals, INC. | $166.34 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $149.50 | 2019-2025 | Libtayo, Lynozyfic |
| Stemline Therapeutics INC. | $148.82 | 2023-2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $134.38 | 2019-2024 | Xarelto |
| Epizyme, INC. | $133.56 | 2021-2022 | |
| Mirati Therapeutics, INC. | $129.37 | 2023 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $110.38 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $107.65 | 2024-2025 | Ultomiris |
| Mylan Institutional INC. | $104.99 | 2019 | |
| Aveo Pharmaceuticals, INC. | $102.15 | 2022-2025 | Fotivda |
| Pharmaand Gmbh | $101.04 | 2024-2025 | Rubraca |
| Jazz Pharmaceuticals INC. | $99.24 | 2020-2021 | |
| Adc Therapeutics America, INC. | $92.99 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.79 | 2019 | |
| Puma Biotechnology, INC. | $78.09 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $69.55 | 2019-2024 | Odomzo, Yonsa |
| Clovis Oncology, INC. | $65.45 | 2019-2020 | |
| Taiho Oncology, INC. | $63.44 | 2019-2023 | |
| Kyowa Kirin, INC. | $61.42 | 2020-2022 | |
| Geron Corporation | $60.86 | 2025 | Rytelo |
| Verastem, INC. | $53.18 | 2019-2020 | |
| Organon LLC | $50.75 | 2021-2022 | |
| Blueprint Medicines Corporation | $47.86 | 2025 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $47.43 | 2021 | |
| Myriad Genetic Laboratories, INC. | $41.50 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $39.81 | 2023 | Monoferric |
| Genmab U.S., INC. | $39.59 | 2023-2024 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $38.52 | 2024 | Onivyde, Somatuline Depot |
| Dova Pharmaceuticals | $38.14 | 2019-2020 | |
| Cti Biopharma Corp. | $37.98 | 2023 | Vonjo |
| Beone Medicines USA, INC. | $36.38 | 2025 | Tevimbra, Brukinsa |
| Tesaro, INC. | $35.52 | 2019 | |
| Ethicon US, LLC | $35.43 | 2019 | |
| Telix Pharmaceuticals | $35.09 | 2025 | |
| Dendreon Pharmaceuticals LLC | $34.44 | 2025 | Provenge |
| Morphosys, US INC. | $24.06 | 2023 | Monjuvi |
| Tempus Ai, INC | $23.71 | 2024 | Xt Cdx |
| Sobi, INC | $23.36 | 2023 | |
| Amneal Pharmaceuticals LLC | $22.75 | 2024 | Neulasta, Avastin, Neupogen |
| Sanofi-Aventis U.S. LLC | $21.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jolly Varki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.